Patients who meet the clinical criteria can be prescribed GLP-1-based RAs therapies depending on availability
When approved options may arrive CagriSema may reach the market within the next one to two years based on current trial timelines and regulatory trajectories
The sum of evidence suggests that, when detected, the use of GLP-1/GIP agonists is associated with the development of mild DR or a slight worsening of existing retinopathy
The mass spectrometry analyses were performed with a MALDI-ToF Voyager-DE STR instrument (Applied Biosystems, Framingham, MA), equipped with a 337 nm nitrogen laser and operating in reflector mode
30-Day (90 Count) $39.95 per Bottle $39.95 60-Day (180 Count) $34.95 per Bottle, Save $10 $34.95 Save $10 90-Day (270 Count) $29.95 per Bottle, Save $30 $29.95 Save $30 Your First Purchase Includes FREE access to myGOLO online resources
Boerner highlighted 11 late-stage program readouts in 2026 across six potential new products